254:
35:
462:
In combination with a peptide antigen, α-GalCer is able to stimulate a strong immune response against the epitope. The CD1d:glycolipid:TCR interaction activates the iNKT cell which can then activate the dendritic cell. This causes the release of a range of cytokines and licenses the dendritic cell to
123:
277:
InChI=1S/C50H99NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(54)51-42(41-59-50-49(58)48(57)47(56)44(40-52)60-50)46(55)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-53,55-58H,3-41H2,1-2H3,(H,51,54)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1
479:
Morita, Masahiro; Motoki, Kazuhiro; Akimoto, Kohji; Natori, Takenori; Sakai, Teruyuki; Sawa, Eiji; Yamaji, Kazuo; Koezuka, Yasuhiko; Kobayashi, Eiichi (1995-06-01). "Structure-Activity
Relationship of .alpha.-Galactosylceramides against B16-Bearing Mice".
463:
activate a peptide-specific T cell response. This adjuvant acts through this cellular interaction, rather than through classic pattern recognition receptor pathways.
293:
584:
Cerundolo, Vincenzo; Silk, Jonathan D.; Masri, S. Hajar; Salio, Mariolina (January 2009). "Harnessing invariant NKT cells in vaccination strategies".
268:
386:
211:
454:
of the iNKT cell is able to bind the CD1d:glycolipid complex leading to iNKT cell activation in both mice and humans.
232:
175:
60:
47:
413:
derived from structure-activity relationship studies of galactosylceramides isolated from the marine
249:
640:
524:
89:
617:
135:
609:
601:
566:
548:
505:
497:
593:
556:
540:
489:
316:
99:
220:
645:
451:
423:
253:
155:
34:
17:
380:
561:
528:
634:
368:
621:
200:
427:
410:
347:
605:
552:
501:
443:
613:
570:
509:
544:
493:
301:
CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N(CO1((((O1)CO)O)O)O)((CCCCCCCCCCCCCC)O)O
187:
418:
414:
166:
597:
379:
Except where otherwise noted, data are given for materials in their
146:
122:
112:
529:"Going both ways: Immune regulation via CD1d-dependent NKT cells"
447:
237:
373:189–190 °C (372–374 °F; 462–463 K)
199:
98:
8:
252:
26:
560:
219:
471:
298:
273:
248:
280:Key: VQFKFAKEUMHBLV-BYSUZVQFSA-N
174:
154:
7:
190:
442:α-GalCer is a potent activator of
68:-oxy}octadecan-2-yl]hexacosanamide
25:
533:Journal of Clinical Investigation
334:
328:
33:
383:(at 25 °C , 100 kPa).
482:Journal of Medicinal Chemistry
337:
322:
1:
438:Immunostimulatory properties
662:
586:Nature Reviews Immunology
377:
309:
289:
264:
82:
74:
59:
46:
41:
32:
18:Alpha-Galactosylceramide
450:antigen. The invariant
422:. α-GalCer is a strong
61:Systematic IUPAC name
28:α-Galactosylceramide
545:10.1172/jci200423594
525:Kronenberg, Mitchell
399:α-Galactosylceramide
494:10.1021/jm00012a018
355: g·mol
136:Beilstein Reference
29:
523:Godfrey, Dale I.;
419:Agelas mauritianus
387:Infobox references
27:
539:(10): 1379–1388.
488:(12): 2176–2187.
458:Adjuvant activity
430:activity in many
426:and shows potent
409:) is a synthetic
395:Chemical compound
393:
392:
233:CompTox Dashboard
124:Interactive image
77:α-GalCer, KRN7000
16:(Redirected from
653:
626:
625:
581:
575:
574:
564:
520:
514:
513:
476:
354:
339:
336:
330:
324:
317:Chemical formula
257:
256:
241:
239:
223:
203:
192:
178:
158:
126:
102:
37:
30:
21:
661:
660:
656:
655:
654:
652:
651:
650:
631:
630:
629:
598:10.1038/nri2451
583:
582:
578:
522:
521:
517:
478:
477:
473:
469:
460:
452:T cell receptor
440:
424:immunostimulant
396:
389:
384:
352:
342:
333:
327:
319:
305:
302:
297:
296:
285:
282:
281:
278:
272:
271:
260:
242:
235:
226:
206:
193:
181:
161:
138:
129:
116:
105:
92:
78:
70:
69:
55:
54:-hexacosanamide
23:
22:
15:
12:
11:
5:
659:
657:
649:
648:
643:
633:
632:
628:
627:
576:
527:(2004-11-15).
515:
470:
468:
465:
459:
456:
446:, and a model
439:
436:
394:
391:
390:
385:
381:standard state
378:
375:
374:
371:
365:
364:
361:
357:
356:
350:
344:
343:
340:
331:
325:
320:
315:
312:
311:
307:
306:
304:
303:
300:
292:
291:
290:
287:
286:
284:
283:
279:
276:
275:
267:
266:
265:
262:
261:
259:
258:
250:DTXSID40935847
245:
243:
231:
228:
227:
225:
224:
216:
214:
208:
207:
205:
204:
196:
194:
186:
183:
182:
180:
179:
171:
169:
163:
162:
160:
159:
151:
149:
143:
142:
139:
134:
131:
130:
128:
127:
119:
117:
110:
107:
106:
104:
103:
95:
93:
88:
85:
84:
80:
79:
76:
72:
71:
64:
63:
57:
56:
50:
44:
43:
39:
38:
24:
14:
13:
10:
9:
6:
4:
3:
2:
658:
647:
644:
642:
639:
638:
636:
623:
619:
615:
611:
607:
603:
599:
595:
591:
587:
580:
577:
572:
568:
563:
558:
554:
550:
546:
542:
538:
534:
530:
526:
519:
516:
511:
507:
503:
499:
495:
491:
487:
483:
475:
472:
466:
464:
457:
455:
453:
449:
445:
437:
435:
433:
429:
425:
421:
420:
416:
412:
408:
404:
400:
388:
382:
376:
372:
370:
369:Melting point
367:
366:
363:White powder
362:
359:
358:
351:
349:
346:
345:
321:
318:
314:
313:
308:
299:
295:
288:
274:
270:
263:
255:
251:
247:
246:
244:
234:
230:
229:
222:
218:
217:
215:
213:
210:
209:
202:
198:
197:
195:
189:
185:
184:
177:
173:
172:
170:
168:
165:
164:
157:
153:
152:
150:
148:
145:
144:
140:
137:
133:
132:
125:
121:
120:
118:
114:
109:
108:
101:
97:
96:
94:
91:
87:
86:
81:
73:
67:
62:
58:
53:
49:
45:
40:
36:
31:
19:
592:(1): 28–38.
589:
585:
579:
536:
532:
518:
485:
481:
474:
461:
441:
431:
417:
406:
402:
398:
397:
176:ChEMBL384200
156:CHEBI:466659
83:Identifiers
75:Other names
65:
51:
428:anti-tumour
360:Appearance
310:Properties
100:158021-47-7
641:Immunology
635:Categories
467:References
444:iNKT cells
411:glycolipid
348:Molar mass
221:WX671898JF
111:3D model (
90:CAS Number
48:IUPAC name
606:1474-1741
553:0021-9738
502:0022-2623
622:38675164
614:19079136
571:15545985
434:models.
403:α-GalCer
141:7326597
510:7783149
432:in vivo
407:KRN7000
353:858.340
201:2826713
188:PubChem
646:Lipids
620:
612:
604:
569:
562:525753
559:
551:
508:
500:
415:sponge
294:SMILES
167:ChEMBL
42:Names
618:S2CID
269:InChI
147:ChEBI
113:JSmol
610:PMID
602:ISSN
567:PMID
549:ISSN
506:PMID
498:ISSN
448:CD1d
212:UNII
594:doi
557:PMC
541:doi
537:114
490:doi
238:EPA
191:CID
637::
616:.
608:.
600:.
588:.
565:.
555:.
547:.
535:.
531:.
504:.
496:.
486:38
484:.
405:,
332:99
326:50
624:.
596::
590:9
573:.
543::
512:.
492::
401:(
341:9
338:O
335:N
329:H
323:C
240:)
236:(
115:)
66:N
52:N
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
